Advertisement

Best of ASCO - 2015 Annual Meeting

 

2014 BOA Seattle Program Agenda

Jump to day: Friday Saturday

Faculty Disclosures


Friday, August 22, 2014
 

7:00 AM —  3:00 PM

Exhibits Open

7:00 AM —    7:55 AM

Complimentary Continental Breakfast

7:55 AM — 
8:00 AM

Welcome and Chair Remarks
Alan P. Venook, MD - University of California, San Francisco

8:00 AM —   8:50 AM

Gastrointestinal (Colorectal) Cancer
George A. Fisher, MD - Stanford University

  • Abstract LBA3: CALGB/SWOG 80405: Phase III trial of irinotecan/5-FU/leucovorin (FOLFIRI) or oxaliplatin/5- U/leucovorin (mFOLFOX6) with bevacizumab (BV) or cetuximab (CET) for patients (pts) with KRAS wild-type (wt) untreated metastatic adenocarcinoma of the colon or rectum (MCRC).  (Alan P. Venook)
  • Abstract 3500: Preoperative chemoradiotherapy and postoperative chemotherapy with 5-fluorouracil and oxaliplatin versus 5-fluorouracil alone in locally advanced rectal cancer: Results of the German CAO/ARO/AIO-04 randomized phase III trial. (Claus Rodel)
  • Abstract 3503^: Maintenance strategy with fluoropyrimidines (FP) plus Bevacizumab (Bev), Bev alone, or no treatment, following a standard combination of FP, oxaliplatin (Ox), and Bev as first-line treatment for patients with metastatic colorectal cancer (mCRC): A phase III non-inferiority trial (AIO KRK 0207). (Dirk Arnold)
  • Abstract 3504: Final results and subgroup analyses of the phase 3 CAIRO3 study: Maintenance treatment with capecitabine + bevacizumab versus observation after induction treatment with chemotherapy + bevacizumab in metastatic colorectal cancer (mCRC). (Miriam Koopman)
  • Abstract 3507: Prognostic impact of deficient mismatch repair (dMMR) in 7,803 stage II/III colon cancer (CC) patients (pts): A pooled individual pt data analysis of 17 adjuvant trials in the ACCENT database. (Daniel J. Sargent)
  • 50th Anniversary-Themed Education Session: 50 Years of Fluorouracil, Radiation, and Surgery: What We've Learned, Recent Advances, and How to Treat Patients Today

8:50 AM —   9:40 AM

Gastrointestinal (Noncolorectal) Cancer
Andrew H. Ko, MD - University of California, San Francisco

  • Abstract 4000: A randomized double-blind phase 2 study of ruxolitinib (RUX) or placebo (PBO) with capecitabine (CAPE) as second-line therapy in patients (pts) with metastatic pancreatic cancer (mPC). (Herbert Hurwitz) 

  • Abstract 4003: Phase III study of apatinib in advanced gastric cancer: A randomized, double-blind, placebo-controlled trial. (Shukui Qin)    

  • Abstract 4005: RAINBOW: A global, phase III, randomized, double-blind study of ramucirumab (RAM) plus paclitaxel (PTX) versus placebo (PL) plus PTX in the treatment of metastatic gastroesophageal junction and gastric adenocarcinoma (mGC) following disease progression on first-line platinum- and fluoropyrimidine-containing combination therapy—Efficacy analysis in Japanese and Western patients. (Shuichi Hironaka)

  • Abstract 4006^: STORM: A phase III randomized, double-blind, placebo-controlled studytrial of adjuvant sorafenib as adjuvant treatment in the prevention ofafter resection or ablation to prevent recurrence of hepatocellular carcinoma (HCC).  (Jordi Bruix) 

  • Abstract 4008: Phase III trial to compare capecitabine/cisplatin (XP) versus XP plus concurrent capecitabine-radiotherapy in gastric cancer (GC): The final report on the ARTIST trial. (Jeeyun Lee)
  • 50th Anniversary-Themed Education Session: The Past, Present, and Future of Noncolorectal Gastrointestinal Cancers: Have We Moved the Bar?

9:40 AM —   10:00 AM

Break

10:00 AM —   10:45 AM

Breast Cancer - Triple-Negative/Local Therapy
Stephen K. L. Chia, MD - BC Cancer Agency

  • Abstract 510: Expression of immunologic genes in triple-negative and HER2-positive breast cancer in the neoadjuvant GEPARSIXTO trial: Prediction of response to carboplatin-based chemotherapy. (Carsten Denkert)

  • Abstract 511: Tracking tumor-specific mutations in circulating-free DNA to predict early relapse after treatment of primary breast cancer. (Nicholas C. Turner)

  • Abstract 1005: Pathological complete response (pCR) rates after carboplatin-containing neoadjuvant chemotherapy in patients with germline BRCA (gBRCA) mutation and triple-negative breast cancer (TNBC): Results from GeparSixto. (Gunter Von Minckwitz) 

  • Abstract 1017: Randomized phase II study of weekly paclitaxel with or without carboplatin followed by cyclophosphamide/epirubicin/5-fluorouracil as neoadjuvant chemotherapy for stage II/IIIA HER2-negative breast cancer. (Kenji Tamura)

  • Abstract 1019^: Cisplatin with or without rucaparib after preoperative chemotherapy in patients with triple-negative breast cancer (TNBC): Hoosier Oncology Group BRE09-146. (Sujaata Dwadasi)
  • 50th Anniversary-Themed Education Session: 50 Years of Advances in Breast Cancer Treatment: What Have We Learned? Where Are We Going?

10:45 AM — 11:30 AM

Breast Cancer - HER2/ER+
Sara A. Hurvitz, MD - University of California, Los Angeles

  • Abstract LBA1: Randomized comparison of adjuvant treatment with aromatase inhibitor (AI) exemestane (E) plus ovarian function suppression (OFS) vs. tamoxifen (T) plus OFS in premenopausal women with hormone receptor-positive (HR+) early breast cancer (BC): Joint analysis of IBCSG TEXT and SOFT trials. (Olivia Pagani)

  • Abstract LBA4: First results from the phase III ALTTO trial (BIG 2-06; NCCTG [Alliance] N063D) comparing one year of anti-HER2 therapy with lapatinib alone (L), trastuzumab alone (T), their sequence (T→L), or their combination (T+L) in the adjuvant treatment of HER2-positive early breast cancer (EBC). (Martine J. Piccart-Gebhart)

  • Abstract 500: Bevacizumab (Bv) in the adjuvant treatment of HER2-negative breast cancer: Final results from Eastern Cooperative Oncology Group E5103. (Kathy Miller)

  • Abstract 504: Prognostic associations of 25OH vitamin D in NCIC CTG MA.21, a phase III adjuvant RCT of three chemotherapy regimens (EC/T, CEF, AC/T) in high-risk breast cancer (BC). (Ana Elisa Lohmann)

  • Abstract 508: Efficacy of adjuvant trastuzumab (T) compared with no T for patients (pts) with HER2-positive breast cancer and tumors ≤ 2cm: A meta-analysis of the randomized trastuzumab trials. (Ciara Catherine Maria O'Sullivan)

11:30 AM —   12:00 PM

Sarcoma
Robin L. Jones, MD - Seattle Cancer Care Alliance

  • Abstract 10506: A phase 2 study of ponatinib in patients (pts) with advanced gastrointestinal stromal tumors (GIST) after failure of tyrosine kinase inhibitor (TKI) therapy: Initial report. (Michael C. Heinrich)
  • Abstract 10508: Long-term disease control of advanced gastrointestinal stromal tumors (GIST) with imatinib (IM): 10-year outcomes from SWOG phase III intergroup trial S0033. (George D. Demetri)
  • Abstract 10509: Predictive biomarker profiling of > 1,900 sarcomas: Identification of potential novel treatment modalities. (Sujana Movva)
  • 50th Anniversary-Themed Education Session: Golden Jubilee: 50 Years of Advances in Sarcoma

12:00 PM —   12:45 PM

Networking Lunch with Faculty (with complimentary boxed lunch)

Meet at designated tables to discuss issues in a particular disease site with faculty and fellow attendees.

12:45 PM —   1:15 PM

Faculty Case Question-and-Answer Panel:  Breast and Gastointestinal Cancers

Open-attendance question-and-answer panel with faculty, where attendees can seek the panel's expert advice on challenging patient cases and issues raised during the Meeting presentations.

  • George A. Fisher, MD - Stanford University
  • Andrew H. Ko, MD - University of California, San Francisco
  • Stephen K. L. Chia, MD - BC Cancer Agency
  • Sara A. Hurvitz, MD - University of California, Los Angeles

1:15 PM —     2:00 PM 

Education Session
Rena M. Conti, PhD - The University of Chicago

2:00 PM —      2:40 PM

Patient and Survivor Care
Arif Kamal, MD - Duke University

  • Abstract LBA9500^: Efficacy and safety of continued zoledronic acid every 4 weeks versus every 12 weeks in women with bone metastases from breast cancer: Results of the OPTIMIZE-2 trial. (Gabriel N. Hortobagyi)
  • Abstract 9503Aprepitant versus metoclopramide, both combined with dexamethasone, for preventing cisplatin-induced delayed emesis: A randomized, double-blind study. (Fausto Roila)
  • Abstract 9506: Increasing cardiovascular screening in at-risk adult survivors of pediatric malignancies: A randomized controlled trial. (Melissa M. Hudson)
  • Abstract 9507: Impact of vaginal dehydroepiandosterone (DHEA) on vaginal symptoms in female cancer survivors: Trial N10C1 (Alliance). (Debra L. Barton)
  • Abstract LBA9513: Benefits of immediate versus delayed palliative care to informal family caregivers of persons with advanced cancer: Outcomes from the ENABLE III randomized clinical trial. (J. Nicholas Dionne-Odom)
  • Abstract LBA9514: Managing comorbidities in oncology: A multisite randomized controlled trial of continuing versus discontinuing statins in the setting of life-limiting illness. (Amy Pickar Abernethy)
  • 50th Anniversary-Themed Education Session: Cancer Survivorship Programs Across Different Health Care Settings: Past, Present and Future

2:40 PM —     3:00 PM 

Break

3:00 PM —    3:40 PM

Melanoma/Skin Cancers
Kevin Kim, MD - California Pacific Medical Center

  • Abstract LBA9000^: Efficacy and safety of the anti-PD-1 monoclonal antibody MK-3475 in 411 patients (pts) with melanoma (MEL). (Antoni Ribas)
  • Abstract 9002: Long-term survival of ipilimumab-naive patients (pts) with advanced melanoma (MEL) treated with nivolumab (anti-PD-1, BMS-936558, ONO-4538) in a phase I trial. (F. Stephen Hodi)
  • Abstract LBA9003^: Survival, response duration, and activity by BRAF mutation (MT) status of nivolumab (NIVO, anti-PD-1, BMS-936558, ONO-4538) and ipilimumab (IPI) concurrent therapy in advanced melanoma (MEL). (Mario Sznol)
  • Abstract LBA9008: Ipilimumab versus placebo after complete resection of stage III melanoma: Initial efficacy and safety results from the EORTC 18071 phase III trial. (Alexander M. Eggermont)
  • Abstract 9011^: COMBI-d: A randomized, double-blinded, Phase III study comparing the combination of dabrafenib and trametinib to dabrafenib and trametinib placebo as first-line therapy in patients (pts) with unresectable or metastatic BRAFV600E/k mutation-positive cutaneous melanoma. (Georgina V. Long)
  • 50th Anniversary-Themed Education Session: From Coley to Cure? Past, Present, and Future of Immunotherapy for Melanoma.

3:40 PM —     4:30 PM

Community Oncology Town Hall: Ongoing and Future Issues for Practice 

Moderator:

John V. Cox, DO, MBA, FASCO - Texas Oncology PA

Panelists:

  • Vicky E. Jones, MD - North Star Lodge Cancer Center
  • Robin Zon, MD, FACP, FASCO - Michiana Hematology Oncology
 

 

 Saturday, August 23, 2014
 

7:00 AM —   8:00 AM

Complimentary Continental Breakfast Provided

8:00 AM —    8:50 AM

Genitourinary (Prostate) Cancer
Evan Y. Yu, MD - Seattle Cancer Care Alliance

  • Abstract LBA2: Impact on overall survival (OS) with chemohormonal therapy versus hormonal therapy for hormone sensitive newly metastatic prostate cancer (mPrCa): An ECOG-led phase III randomized trial. (Christopher Sweeney)
  • Abstract 5001Androgen receptor splice variant, AR-V7, and resistance to enzalutamide and abiraterone in men with metastatic castration-resistant prostate cancer (mCRPC). (E. S. Antonarakis) 
  • Abstract 5003: Immediate versus deferred initiation of androgen deprivation therapy in prostate cancer patients with PSA-only relapse. (Xabier Garcia-Albeniz)
  • Abstract 5008: Phase 3, randomized, placebo-controlled trial of orteronel (TAK-700) plus prednisone in patients (pts) with chemotherapy-naïve metastatic castration-resistant prostate cancer (mCRPC) (ELM-PC 4 trial). (Ronald De Wit)
  • 50th Anniversary-Themed Education Session: 50 Years of Progress in Advanced Prostate Cancer

8:50 AM —   9:40 AM

Genitourinary (Nonprostate) Cancer
Sumanta K. Pal, MD - City of Hope

  • Abstract 4500: Final results of EORTC intergroup randomized phase III trial comparing immediate versus deferred chemotherapy after radical cystectomy in patients with pT3T4 and/or N+ M0 transitional cell carcinoma (TCC) of the bladder. (Cora N. Sternberg)
  • Abstract 4505: Everolimus versus sunitinib prospective evaluation in metastatic non-clear cell renal cell carcinoma (The ESPN Trial): A multicenter randomized phase 2 trial. (Nizar M. Tannir)
  • Abstract 5009: Nivolumab for metastatic renal cell carcinoma (mRCC): Results of a randomized, dose-ranging phase II trial. (Robert J. Motzer)
  • Abstract 5011: Inhibition of PD-L1 by MPDL3280A leads to clinical activity in pts with metastatic urothelial bladder cancer (UBC). (Thomas Powles)
  • Abstract 5012: Immunomodulatory activity of nivolumab in previously treated and untreated metastatic renal cell carcinoma (mRCC): Biomarker-based results from a randomized clinical trial. (Toni K. Choueiri)

9:40 AM —   10:00 AM

Break

10:00 AM —    10:40 AM

Head and Neck Cancer
Renato G. Martins, MD, MPH - Seattle Cancer Care Alliance

  • Abstract 6001: Impact of p16 status on the results of the phase III cetuximab (cet)/radiotherapy (RT). (David I. Rosenthal)
  • Abstract 6004: Concomitant chemoradiation (CRT) or cetuximab/RT (CET/RT)  versus induction docetaxel, cisplatin, and 5-fluorouracil (TPF) followed by CRT or CET/RT in patients with locally advanced squamous cell  carcinoma of head and neck (LASCCHN): A randomized phase III factorial study (NCT01086826). (Maria Ghi)
  • Abstract 6005: Final analysis: A randomized, blinded, placebo (P)-controlled phase III study of adjuvant postoperative lapatinib (L) with concurrent chemotherapy and radiation therapy (CH-RT) in high-risk patients with squamous cell carcinoma of the head and neck (SCCHN). (Kevin J. Harrington)
  • Abstract LBA6006: E1308: Reduced-dose IMRT in human papilloma virus (HPV)-associated resectable oropharyngeal squamous carcinomas (OPSCC) after clinical complete response (cCR) to induction chemotherapy (IC). (Anthony Cmelak)
  • Abstract LBA6008: A phase 3, multicenter, double-blind, placebo-controlled trial of lenvatinib (E7080) in patients with 131I-refractory differentiated thyroid cancer (SELECT). (Martin Schlumberger)
  • 50th Anniversary-Themed Education Session: Migration from Carcinogen to Virus: 50 Years of Evolution in Epidemiology and Treatment of Head and Neck Cancer

10:40 AM —    11:30 AM

Lung Cancer - Non-Small Cell Metastatic
H. Jack West, MD - Swedish Cancer Institute

  • Abstract 8002: First-line crizotinib versus pemetrexed/cisplatin or pemetrexed/carboplatin in patients with advanced ALK-positive nonsquamous non-small cell lung cancer (NSCLC): Results of a phase III study (PROFILE 1014). (Tony Mok)
  • Abstract 8003^: Ceritinib in advanced anaplastic lymphoma kinase (ALK)-rearranged (ALK+) non-small cell lung cancer (NSCLC): Results of the ASCEND-1 trial. (Dong-Wan Kim)
  • Abstract 8005 Erlotinib plus bevacizumab (EB) versus erlotinib alone (E) as first-line treatment for advanced EGFR mutation–positive nonsquamous non-small cell lung cancer (NSCLC): An open-label randomized trial. (Terufumi Kato)
  • Abstract LBA8006^:  REVEL: A randomized, double-blind, phase III study of docetaxel (DOC) and ramucirumab (RAM; IMC-1121B) versus DOC and placebo in the treatment of stage IV non-small cell lung cancer (NSCLC) following disease progression after one prior platinum-based therapy. (Maurice Perol)
  • Abstract 8008^: A randomized, multicenter, open-label, phase III study of gemcitabine-cisplatin (GC) chemotherapy plus necitumumab (IMC-11F8/LY3012211) versus GC alone in the first-line treatment of patients (pts) with stage IV squamous non-small cell lung cancer (sq-NSCLC). (Nick Thatcher)
  • Abstract 8009^: Clinical activity of the mutant selective EGFR inhibitor AZD9291 in patients (pts) with EGFR inhibitor resistant non-small cell lung cancer (NSCLC). (Pasi A. Janne)

11:30 AM —    12:00 PM

Lung Cancer - Non-Small Cell/Local-Regional/Small Cell/Other Thoracic Cancers
Edward B. Garon, MD - University of California, Los Angeles

  • Abstract 7500: A multinational phase III randomized trial with or without consolidation chemotherapy using docetaxel and cisplatin after concurrent chemoradiation in inoperable stage III non-small cell lung cancer (CCheIN). (Keunchil Park)
  • Abstract 7501: A randomized double blind phase 3 trial of adjuvant erlotinib (E) versus placebo (P) following complete tumor resection with or without adjuvant chemotherapy in patients (pts) with stage IB-IIIA EGFR positive (IHC/FISH) non-small cell lung cancer (NSCLC): RADIANT results. (Karen Kelly)
  • Abstract 7502: Randomized trial on thoracic radiotherapy (TRT) in extensive-stage small cell lung cancer. (Ben J. Slotman)
  • Abstract 7503: Prophylactic cranial irradiation (PCI) has a detrimental effect on the overall survival (OS) of patients (pts) with extensive disease small cell lung cancer (ED-SCLC): Results of a Japanese randomized phase III trial. (Takashi Seto)
  • 50th Anniversary-Themed Education Session: 50 Years of Lung Cancer: The Current Status of Therapy for Non-Small Cell Lung Cancer—Adjuvant Therapy, Chemoradiotherapy, and Systemic Treatment

12:00 PM —    12:45 PM

Networking Lunch with Faculty (with complimentary boxed lunch)

Meet at designated tables to discuss issues in a particular disease site with faculty and fellow attendees.

12:45 PM —    1:15 PM

Faculty Case Question-and-Answer Panel: Genitourinary and Lung Cancers

Open-attendance question-and-answer panel with faculty, where attendees can seek the panel's expert advice on challenging patient cases and issues raised during the Meeting presentations.

  • Evan Y. Yu, MD - Seattle Cancer Care Alliance
  • Sumanta K. Pal, MD - City of Hope
  • H. Jack West, MD - Swedish Cancer Institute
  • Edward B. Garon, MD - University of California, Los Angeles

1:15 PM —    2:00 PM

Education Session
Douglas Blayney, MD, FASCO - Stanford Cancer Center

2:00 PM — 2:40 PM

Gynecologic Cancer
Matthew A. Powell, MD - Washington University School of Medicine

  • Abstract LBA5500: A randomized phase 2 trial comparing efficacy of the combination of the PARP inhibitor olaparib and the antiangiogenic cediranib against olaparib alone in recurrent platinum-sensitive ovarian cancer.  (Joyce Liu)
  • Abstract 5502: Molecular subgroup of high-grade serous ovarian cancer (HGSOC) as a predictor of outcome following bevacizumab. (Charlie Gourley)
  • Abstract 5504: Progression-free survival in ovarian cancer patients in second remission is improved with mucin-1 autologous dendritic cell therapy. (Heidi J. Gray)
  • Abstract 5507: Randomized phase III trial of paclitaxel/carboplatin (PC) versus cisplatin/irinotecan (CPT-P) as first-line chemotherapy in patients with clear cell carcinoma (CCC) of the ovary: A Japanese Gynecologic Oncology Group (JGOG)/GCIG study. (Aikou Okamoto)
  • Abstract 5508: Comparison of treatment invasiveness between upfront debulking surgery versus interval debulking surgery following neoadjuvant chemotherapy for stage III/IV ovarian, tubal, and peritoneal cancers in phase III randomized trial: JCOG0602. (Takashi Onda)
  • 50th Anniversary-Themed Education Session: Selecting the Best Therapy for Recurrent Ovarian Cancer: Progress in Response Prediction over the Last 50 Years

2:40 PM —    3:00 PM

Break

3:00 PM —    3:30 PM

Leukemia
Roland B. Walter, MD, PhD - Fred Hutchinson Cancer Research Center

  • Abstract 7005^: Confirmatory open-label, single-arm, multicenter phase 2 study of the BiTE antibody blinatumomab in patients (pts) with relapsed/refractory B-precursor acute lymphoblastic leukemia (r/r ALL). (Max S. Topp)
  • Abstract LBA7008: Randomized comparison of ibrutinib versus ofatumumab in relapsed or refractory (R/R) chronic lymphocytic leukemia/small lymphocytic lymphoma: Results from the phase III RESONATE trial. (John C. Byrd)
  • Abstract 7026: Results of a prospective, randomized, open-label phase 3 study of ruxolitinib (RUX) in polycythemia vera (PV) patients resistant to or intolerant of hydroxyurea (HU): the RESPONSE trial. (Srdan Verstovsek)

3:30 PM —    4:30 PM

Lymphoma and Myeloma
Amit B. Agarwal, MD, PhD - University of Arizona

  • Abstract 8501: Increased rituximab (R) doses eliminate increased risk of elderly male patients with aggressive CD20+ B-cell lymphomas: Results from the SEXIE-R-CHOP-14 trial of the DSHNHL. (Michael Pfreundschuh)

  • Abstract 8505: Interim analysis of a phase 1, open-label, dose-escalation study of SGN-CD19A in patients with relapsed or refractory B-lineage non-Hodgkin lymphoma (NHL). (Andres Forero-Torres)

  • Abstract 8506: Starlyte phase II study of coltuximab ravtansine (CoR, SAR3419) single agent: Clinical activity and safety in patients (pts) with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) (NCT01472887). (Marek Trneny)

  • Abstract 8507: A pilot phase II study with brentuximab vedotin followed by ABVD in patients with previously untreated Hodgkin lymphoma: A preliminary report. (Massimo Federico)

  • Abstract 8510^: Panorama 1: A randomized, double-blind, phase 3 study of panobinostat or placebo plus bortezomib and dexamethasone in relapsed or relapsed and refractory multiple myeloma.  (Paul G. Richardson)

  • Abstract 8511: E1A06: A phase III trial comparing melphalan, prednisone, and thalidomide (MPT) versus melphalan, prednisone, and lenalidomide (MPR) in newly diagnosed multiple myeloma MM).  (A. Keith Stewart)

  • Abstract 8520: Effect of lenalidomide combined with R-CHOP (R2CHOP) on negative prognostic impact of nongerminal center (non-GCB) phenotype in newly diagnosed diffuse large B-cell lymphoma: A phase 2 study. (Grzegorz S. Nowakowski)